Using Recombinant Insulin and Trypsin for Safer Vaccine Production

The production of cell-based vaccines requires robust, consistent and contamination-free upstream processes to ensure both product safety and manufacturing efficiency. Animal-free reagents have become the gold standard in biomanufacturing, addressing critical needs for enhanced consistency and reduced risk of contamination. This webinar explores the pivotal roles of two key reagents: recombinant insulin and trypsin in optimizing cell-based vaccine production across commonly used cell systems, including Vero cells and HEK293 cells.

Recombinant insulin has demonstrated significant value in vaccine manufacturing by improving cell culture performance, enhancing viral yield and supporting consistent production across diverse vaccine platforms. Testing in Vero and HEK293 cell systems has shown insulin’s ability to boost productivity. Complementing this with high-purity recombinant trypsin addresses critical safety concerns associated with traditional animal-derived trypsin used in virus expansion and activation processes, while also improving virus infectivity and quality. Through a controlled production process that maintains the inactive form until stabilization, this recombinant trypsin delivers consistent high β-trypsin content while eliminating adventitious contamination risks.

The strategic implementation of recombinant insulin and trypsin delivers enhanced safety, improved efficiency and cost-effective vaccine production across key cell systems.

Register for this webinar to learn how recombinant insulin improves viral yield and manufacturing efficiency in vaccine production.

Speakers

Sara Bursomanno, PhD, Senior Global Product Manager, Novo Nordisk Pharmatech A/S

Sara Bursomanno is a seasoned expert in Cancer Biology with over a decade of experience in academic research. Having transitioned to the biopharmaceutical industry over six years ago, Sara has excelled as a Product Manager, focusing on the upstream manufacturing of biological drugs.

Her specialized knowledge in cell culture and protein production allows her to effectively bridge the gap between scientific research and practical industry applications.

Message Presenter

Chantale Julien, Global Product Manager, Novo Nordisk Pharmatech A/S

With over 20 years of experience in the pharmaceutical industry, Chantale is currently a Global Product Manager at Novo Nordisk Pharmatech A/S, where she manages several product portfolios.

Her role encompasses providing technical and scientific support, strategic market positioning and adherence to GXP requirements. Throughout her career, she has held positions at the Canadian Food Inspection Agency, Novonesis (previously Chr. Hansen A/S) and Cook Medical, in various management roles that emphasize compliance, life-cycle product management and API distribution.

Mrs. Julien earned her Master’s degree in Animal Sciences from Université Laval in Québec, Canada.

Message Presenter